会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明授权
    • Automatic communication protocol test system with message/sequence edit function and test method using the same
    • 具有消息/序列编辑功能的自动通信协议测试系统及使用相同的测试方法
    • US06560723B1
    • 2003-05-06
    • US09472160
    • 1999-12-27
    • Yumi Matsui
    • Yumi Matsui
    • H02H305
    • H04L43/50
    • A line monitoring function unit collects message information and sequence information from an existing communication network. A data analyzing function unit converts the collected message information and sequence information into significant information defined for each communication protocol to analyze detailed information on the communication protocol. A scenario creating function unit creates/edits a test scenario and test message with the detailed information obtained by the data analyzing function unit. A data converting function unit converts the data from the scenario creating function unit. A test message input/output function unit executes a communication protocol test in accordance with a sequence of the test scenario obtained from the scenario creating function unit. A log buffer accumulates log information collected during the communication protocol test. An edit searching function unit accesses the scenario creating function unit to obtain a scenario of interest with a search keyword for edit of the information obtained at the scenario creating function unit.
    • 线路监控功能单元从现有通信网络收集消息信息和序列信息。 数据分析功能单元将收集的消息信息和序列信息转换成为每个通信协议定义的重要信息,以分析关于通信协议的详细信息。 场景创建功能单元利用数据分析功能单元获得的详细信息创建/编辑测试场景和测试消息。 数据转换功能单元转换来自脚本创建功能单元的数据。 测试消息输入/输出功能单元根据从场景创建功能单元获得的测试场景的顺序执行通信协议测试。 日志缓冲区累积在通信协议测试期间收集的日志信息。 编辑搜索功能单元访问场景创建功能单元,以获得用于编辑在场景创建功能单元获得的信息的搜索关键字感兴趣的场景。
    • 7. 发明申请
    • NOVEL PHENYLPYRROLE DERIVATIVE
    • 新颖的灵性衍生物
    • US20120022075A1
    • 2012-01-26
    • US13198819
    • 2011-08-05
    • Akihiro FURUKAWATakehiro FUKUZAKIYukari ONISHIHideki KOBAYASHITakeshi HONDAYumi MATSUIMasahiro KONISHIKenjiro UEDATetsuyoshi MATSUFUJI
    • Akihiro FURUKAWATakehiro FUKUZAKIYukari ONISHIHideki KOBAYASHITakeshi HONDAYumi MATSUIMasahiro KONISHIKenjiro UEDATetsuyoshi MATSUFUJI
    • A61K31/497C07D401/04C07D263/32C07D207/323A61P3/10C07D409/14A61K31/427A61K31/4439A61K31/422A61K31/40C07D277/28C07D241/02
    • C07D413/14C07D207/333C07D207/335C07D207/337C07D401/04C07D403/04C07D413/04C07D417/04C07D417/14
    • The present invention relates to a compound or a pharmacologically acceptable salt thereof having superior glucokinase activating activity, and is a compound represented by general formula (I), or pharmacologically acceptable salt thereof: [wherein, A represents, for example, an oxygen atom or sulfur atom, R1 represents, for example, a C1-C6 alkyl group, a C1-C6 alkoxy group or a C1-C6 halogenated alkyl group, A and R1 together with the carbon atom bonded thereto form a heterocyclic group that may be substituted with 1 to 3 group(s) independently selected from Substituent Group α, R2 represents a phenyl group that may be substituted with 1 to 5 group(s) independently selected from Substituent Group α or a heterocyclic group that may be substituted with 1 to 3 group(s) independently selected from Substituent Group α, R3 represents a hydroxy group or a C1-C6 alkoxy group, and Substituent Group α consists of, for example, a halogen atom, a C1-C6 alkyl group, a C1-C6 alkyl group substituted with 1 or 2 hydroxy group(s), a C1-C6 alkylsulfonyl group, and a group represented by the formula —V—NR5R6 (wherein, V represents a carbonyl group or a sulfonyl group, and R5 and R6 may be the same or different and respectively represent a hydrogen atom or a C1-C6 alkyl group, or R5 and R6 together with the nitrogen atom bonded thereto form a 4- to 6-membered saturated heterocycle that may be substituted with 1 or 2 group(s) independently selected from a C1-C6 alkyl group and a hydroxy group, and the 4- to 6-membered saturated heterocycle may further contain one oxygen atom or nitrogen atom)].
    • 本发明涉及具有优异的葡糖激酶活化活性的化合物或其药理学上可接受的盐,并且是通式(I)表示的化合物或其药理学上可接受的盐:[其中,A表示例如氧原子或 硫原子,R1表示例如C1-C6烷基,C1-C6烷氧基或C1-C6卤代烷基,A和R1与与其结合的碳原子一起形成可以被 1至3个独立地选自取代基组α的基团,R 2表示可以被独立地选自取代基组α的1至5个基团取代的苯基或可被1至3个基团取代的杂环基 独立地选自取代基组α,R3表示羟基或C1-C6烷氧基,取代基组α由例如卤素原子,C1-C6烷基,C1-C6烷基组成 取代 具有1或2个羟基,C1-C6烷基磺酰基和由式-V-NR5R6表示的基团(其中,V表示羰基或磺酰基,R5和R6可以相同) 或不同,分别表示氢原子或C1-C6烷基,或R5和R6与键合的氮原子一起形成可以被1或2个基团独立地取代的4至6元饱和杂环 选自C 1 -C 6烷基和羟基,并且4至6元饱和杂环可以进一步含有一个氧原子或氮原子)]。
    • 8. 发明授权
    • Phenylpyrrole derivative
    • 苯基吡咯衍生物
    • US08017610B2
    • 2011-09-13
    • US12843348
    • 2010-07-26
    • Akihiro FurukawaTakehiro FukuzakiYukari OnishiHideki KobayashiTakeshi HondaYumi MatsuiMasahiro KonishiKenjiro UedaTetsuyoshi Matsufuji
    • Akihiro FurukawaTakehiro FukuzakiYukari OnishiHideki KobayashiTakeshi HondaYumi MatsuiMasahiro KonishiKenjiro UedaTetsuyoshi Matsufuji
    • A61K31/501A61K31/497A61K31/443A61K31/421C07D403/14C07D413/14C07D265/08
    • C07D413/14C07D207/333C07D207/335C07D207/337C07D401/04C07D403/04C07D413/04C07D417/04C07D417/14
    • The present invention relates to a compound or a pharmacologically acceptable salt thereof having superior glucokinase activating activity, and is a compound represented by general formula (I), or pharmacologically acceptable salt thereof: [wherein, A represents, for example, an oxygen atom or sulfur atom, R1 represents, for example, a C1-C6 alkyl group, a C1-C6 alkoxy group or a C1-C6 halogenated alkyl group, A and R1 together with the carbon atom bonded thereto form a heterocyclic group that may be substituted with 1 to 3 group(s) independently selected from Substituent Group α, R2 represents a phenyl group that may be substituted with 1 to 5 group(s) independently selected from Substituent Group α or a heterocyclic group that may be substituted with 1 to 3 group(s) independently selected from Substituent Group α, R3 represents a hydroxy group or a C1-C6 alkoxy group, and Substituent Group α consists of, for example, a halogen atom, a C1-C6 alkyl group, a C1-C6 alkyl group substituted with 1 or 2 hydroxy group(s), a C1-C6 alkylsulfonyl group, and a group represented by the formula —V—NR5R6 (wherein, V represents a carbonyl group or a sulfonyl group, and R5 and R6 may be the same or different and respectively represent a hydrogen atom or a C1-C6 alkyl group, or R5 and R6 together with the nitrogen atom bonded thereto form a 4- to 6-membered saturated heterocycle that may be substituted with 1 or 2 group(s) independently selected from a C1-C6 alkyl group and a hydroxy group, and the 4- to 6-membered saturated heterocycle may further contain one oxygen atom or nitrogen atom)].
    • 本发明涉及具有优异的葡糖激酶活化活性的化合物或其药理学上可接受的盐,并且是通式(I)表示的化合物或其药理学上可接受的盐:[其中,A表示例如氧原子或 硫原子,R1表示例如C1-C6烷基,C1-C6烷氧基或C1-C6卤代烷基,A和R1与与其结合的碳原子一起形成可以被 1至3个独立地选自取代基组α的基团,R 2表示可以被独立地选自取代基组α的1至5个基团取代的苯基或可被1至3个基团取代的杂环基 独立地选自取代基组α,R3表示羟基或C1-C6烷氧基,取代基组α由例如卤素原子,C1-C6烷基,C1-C6烷基组成 取代 具有1或2个羟基,C1-C6烷基磺酰基和由式-V-NR5R6表示的基团(其中,V表示羰基或磺酰基,R5和R6可以相同) 或不同,分别表示氢原子或C1-C6烷基,或R5和R6与键合的氮原子一起形成可以被1或2个基团独立地取代的4至6元饱和杂环 选自C 1 -C 6烷基和羟基,并且4至6元饱和杂环可以进一步含有一个氧原子或氮原子)]。